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For over 60 years, cortical spreading depression (CSD) has
mesmerized neurologists immersed in headache research.
While science and logic are (or, at least, should be)
inseparable, CSD—a largely experimental physiological
reality—has dissociated the two in headache-related
research. Although the need for a fresh pathophysiologic
approach to migraine and other primary headaches unre-
lated to the neuronal (neural) or vascular theories has been
voiced two decades ago [1, 2], and the issue has been
questioned again recently [3, 4], the fascination for CSD as
the basis for migraine remains largely undimmed. Cur-
rently, the pathogenetic role of CSD in migraine is widely
accepted as an immutable fact or truth, and, any challenge
to its role is regarded as almost heretical.
In this issue of TJHP, Yu and colleagues present an
interesting facet of the mechanism of action of ﬂunarizine
in a rat model of CSD. The key ﬁnding is that ﬂunarizine
can alleviate cerebral mitochondrial injury under both
normal and hypoxic conditions, a not unexpected effect
attributed likely to blockade of voltage-gated calcium
channels. However, hypoxia attenuated the protective
effect of ﬂunarizine on the CSD amplitude. In a nutshell,
CSD leads to oxidative stress, or aggravated hypoxic
conditions in the brain, and, these changes can be attenu-
ated by ﬂunarizine.
In extrapolating these experimental results in rats to
humans, and, in particular, to migraine pathophysiology,
certain features need careful consideration. The role of
ﬂunarizine in migraine therapeutics is itself uncertain.
While ﬂunarizine is used (albeit, with low-grade evidence)
for migraine prophylaxis in several countries, it has yet to
be approved for this indication by the United States Food
and Drug Administration. Whereas the US FDA looks for
evidences from randomized clinical trials (RCT) to stamp
its approval of drugs such as ﬂunarizine, the RCT itself is
not without ﬂaws, and, its utility in migraine is limited by
the very nature of the disorder [5]. At a more fundamental
level, ﬂunarizine is a potent vasodilator of the cerebral
vessels. Alcohol and nitroglycerin are well-established
vasodilators that precipitate migraine predictably without
any known effect(s) on CSD. There is, however, a signif-
icant clinical difference between sustained prophylactic
cerebral vasodilatation (ﬂunarizine) and relatively sudden
cerebral vasodilatation (alcohol, nitroglycerin). Neverthe-
less, evidence that ﬂunarizine can provide extended, sat-
isfactory prophylaxis for most migraine patients is
conspicuously sparse.
The limitations of CSD as a pathogenetic model for
human neurological illnesses, particularly migraine, have
been discussed almost exhaustively; additionally, a large
and growing body of evidence indicates that CSD is bio-
logically adaptive or neuroprotective [4]. There is not a
single description of homonymously distributed migrain-
ous scintillating scotoma; the scotoma has always been
described as spreading towards the temporal ﬁeld, right or
left. Even Lashley [6] did not describe spread of his own
migrainous scotoma towards the nasal ﬁeld. As a neuro-
pathologic concept, CSD has spawned much confusion and
speculation, and, has outlived its usefulness. The time is,
perhaps, ripe to bid farewell to an enduring and revered
notion in neurology. Only then, we might step out of the
maze of clinical and therapeutic assumptions that sustain a
prominent role for CSD in human neuropathology. Such
comprehension would also mark the beginning of the end
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DOI 10.1007/s10194-010-0287-zof the stalemate that has gripped migraine research for over
half a century.
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